AU2015259470A1 - Virus like vesicles (VLVs) based vaccines to prevent or treat chronic hepatitis B virus (HBV) infection - Google Patents

Virus like vesicles (VLVs) based vaccines to prevent or treat chronic hepatitis B virus (HBV) infection Download PDF

Info

Publication number
AU2015259470A1
AU2015259470A1 AU2015259470A AU2015259470A AU2015259470A1 AU 2015259470 A1 AU2015259470 A1 AU 2015259470A1 AU 2015259470 A AU2015259470 A AU 2015259470A AU 2015259470 A AU2015259470 A AU 2015259470A AU 2015259470 A1 AU2015259470 A1 AU 2015259470A1
Authority
AU
Australia
Prior art keywords
hbv
hepatitis
virus
antigen
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2015259470A
Other languages
English (en)
Inventor
Tracy Reynolds
Michael ROBEK
John Rose
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yale University
Original Assignee
Yale University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yale University filed Critical Yale University
Publication of AU2015259470A1 publication Critical patent/AU2015259470A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/29Hepatitis virus
    • A61K39/292Serum hepatitis virus, hepatitis B virus, e.g. Australia antigen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5258Virus-like particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53DNA (RNA) vaccination
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/545Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/70Multivalent vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10141Use of virus, viral particle or viral elements as a vector
    • C12N2730/10143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/36011Togaviridae
    • C12N2770/36111Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36141Use of virus, viral particle or viral elements as a vector
    • C12N2770/36143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2810/00Vectors comprising a targeting moiety
    • C12N2810/50Vectors comprising as targeting moiety peptide derived from defined protein
    • C12N2810/60Vectors comprising as targeting moiety peptide derived from defined protein from viruses
    • C12N2810/6072Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses
    • C12N2810/6081Vectors comprising as targeting moiety peptide derived from defined protein from viruses negative strand RNA viruses rhabdoviridae, e.g. VSV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2015259470A 2014-05-16 2015-05-11 Virus like vesicles (VLVs) based vaccines to prevent or treat chronic hepatitis B virus (HBV) infection Abandoned AU2015259470A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461994166P 2014-05-16 2014-05-16
US61/994,166 2014-05-16
PCT/US2015/030100 WO2015175380A1 (en) 2014-05-16 2015-05-11 VIRUS LIKE VESICLES (VLVs) BASED VACCINES TO PREVENT OR TREAT CHRONIC HEPATITIS B VIRUS (HBV) INFECTION

Publications (1)

Publication Number Publication Date
AU2015259470A1 true AU2015259470A1 (en) 2016-11-10

Family

ID=54480490

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2015259470A Abandoned AU2015259470A1 (en) 2014-05-16 2015-05-11 Virus like vesicles (VLVs) based vaccines to prevent or treat chronic hepatitis B virus (HBV) infection

Country Status (8)

Country Link
US (1) US9987353B2 (enExample)
EP (1) EP3143144A4 (enExample)
JP (1) JP2017515508A (enExample)
CN (1) CN106459998A (enExample)
AU (1) AU2015259470A1 (enExample)
BR (1) BR112016026721A2 (enExample)
CA (1) CA2948181A1 (enExample)
WO (1) WO2015175380A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109154004B (zh) * 2016-01-12 2023-06-06 德国亥姆霍兹慕尼黑中心健康与环境研究中心(有限公司) 用于治疗hbv的手段和方法
EP3276006A1 (en) * 2016-07-27 2018-01-31 Theravectys Lentiviral vectors for expression of hepatitis b virus (hbv) antigens
CN110382009A (zh) * 2016-12-29 2019-10-25 富荣吉有限责任公司 Retro-HBV和Lenti-HBV的混合载体及构建体
CN108949790A (zh) * 2017-10-27 2018-12-07 电子科技大学 一种基于基因工程烟草的1,2,3-三氯丙烷生物降解方法
KR20250027279A (ko) * 2018-05-10 2025-02-25 멜버른 헬스 B형 간염 감염 치료를 위한 방법 및 조성물
US20210355168A1 (en) * 2018-10-05 2021-11-18 Rnagene Inc. Chimeric antigen with enhanced multi-immune function through specific binding to target cell, and use thereof
EP4458975A3 (en) * 2019-09-30 2025-02-12 Gilead Sciences, Inc. Hbv vaccines and methods treating hbv
EP4087858A1 (en) 2020-01-10 2022-11-16 Carogen Corporation Compositions and methods of use of oncolytic virus like vesicles
CN113138276B (zh) * 2020-01-19 2022-09-16 厦门万泰凯瑞生物技术有限公司 用于检测HBcAg的方法及抗体
CN113234692B (zh) * 2021-05-11 2022-02-22 华中农业大学 一种包含狂犬病毒糖蛋白的感染性克隆及应用
CN113736750B (zh) * 2021-09-22 2023-03-31 中牧实业股份有限公司 一株盖他病毒毒株及其应用
WO2023133509A2 (en) * 2022-01-08 2023-07-13 Carogen Corporation Multi-antigen therapeutic vaccines to treat or prevent chronic hepatitis b virus infection
WO2023164457A2 (en) * 2022-02-22 2023-08-31 Carogen Corporation Versatile virus-like-vesicles (vlv) platform for infectious diseases and cancer immunotherapy applications
CN115747174A (zh) * 2022-09-15 2023-03-07 武汉大学 重组溶瘤病毒rVSVM51R-C在乙肝性肝癌中的应用
JP2025537544A (ja) * 2022-11-07 2025-11-18 シァメン・ユニヴァーシティ 融合タンパク質及びそれを含む粒状抗原

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009090594A2 (en) 2008-01-11 2009-07-23 Yale University Alphavirus based vectors
US20030099932A1 (en) * 1998-05-12 2003-05-29 Lorens James B. Retroviral vectors with separation sequences
ES2170622B1 (es) * 1999-12-03 2004-05-16 Consejo Superior De Investigaciones Cientificas Clones y vectores infectivos derivados de coronavirus y sus aplicaciones.
CN101355960A (zh) * 2005-10-18 2009-01-28 诺华疫苗和诊断公司 使用α病毒复制子颗粒进行粘膜和全身免疫
WO2015175382A1 (en) * 2014-05-16 2015-11-19 Yale University Evolution of high-titer virus-like vesicles for vaccine applications

Also Published As

Publication number Publication date
JP2017515508A (ja) 2017-06-15
US20170056493A1 (en) 2017-03-02
BR112016026721A2 (pt) 2017-10-31
CN106459998A (zh) 2017-02-22
EP3143144A1 (en) 2017-03-22
EP3143144A4 (en) 2017-12-20
WO2015175380A1 (en) 2015-11-19
CA2948181A1 (en) 2015-11-19
US9987353B2 (en) 2018-06-05

Similar Documents

Publication Publication Date Title
US9987353B2 (en) Virus like vesicles (VLVS) based vaccines to prevent or treat chronic hepatitis B virus (HBV) infection
CN112618707B (zh) 一种SARS-CoV-2冠状病毒疫苗及其制备方法
US11660336B2 (en) Coronavirus disease (COVID-19) vaccine
EP2160197B1 (en) Adenoviral vector encoding malaria antigen
US10435712B2 (en) Evolution of high-titer virus-like vesicles for vaccine applications
US11896658B2 (en) RSV vaccines and methods of production and use thereof
CN110612118A (zh) 用于引起针对hbv的免疫应答的病毒样粒子
EP4087858A1 (en) Compositions and methods of use of oncolytic virus like vesicles
EP4205762A1 (en) Improved dna vaccine for sars-cov-2
CN113151196A (zh) 重组痘苗病毒、痘苗病毒载体疫苗及其应用与制备方法
JP2020537526A (ja) Rsv抗原性タンパク質又はその断片をコードする2つの発現カセットを有するアデノウイルスベクター
JP2021500880A (ja) 2つの発現カセットを有するサルアデノウイルスベクター
Seregin et al. Immunogenicity of West Nile virus infectious DNA and its noninfectious derivatives
US20250121052A1 (en) Sars-cov-2 vaccines
US20240181041A1 (en) Adenovirus SARS-CoV-2 Vaccine
US20250235527A1 (en) Synthetic modified vaccinia ankara (smva) based coronavirus vaccines
WO2018146257A1 (en) Hepatitis e virus vaccine
CN107206035A (zh) 丙型肝炎的治疗和/或预防用药物组合物
WO2024026274A2 (en) Virus-like vesicles (vlvs) based vaccines and methods of preventing, ameliorating, and/or treating covid-19 and/or hepatocellular carcinoma (hcc)
JP2024537791A (ja) 汎コロナウイルスワクチン
HK1108114A (en) Aids vaccine based on replicative vaccinia virus vector

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period